The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma

Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the...

Full description

Bibliographic Details
Main Authors: Atakan Topcu, Akin Ozturk, Ismail Yurtsever, Mehmet Besiroglu, Ayse Irem Yasin, Haci Mehmet Turk, Mesut Seker
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2022-10-01
Series:Biomolecules & Biomedicine
Subjects:
Lung cancer
sarcopenia
erlotinib
adenocarcinoma
prognosis
Online Access:https://www.bjbms.org/ojs/index.php/bjbms/article/view/7147

Internet

https://www.bjbms.org/ojs/index.php/bjbms/article/view/7147

Similar Items